In our recent randomized, double-blinded, placebo-controlled trial, low-dose LGZG effectively improved insulin resistance in overweight/obese NAFLD patients (Xu et al., 2020; Dai et al., 2022), which might be related to the regulation of DNA N6-methyladenine modification of protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and autophagy-related 3 (ATG3) (Dai et al., 2022). Here, ATG3 is linked to metabolic dysfunction-associated steatotic liver disease.